having follicular lymphoma grade II, stage IVA, in April 2004. She received four FND-r cycles after which, on the basis of computed tomography and positron emission tomography restaging, residual disease was observed in the abdomen. She received further chemotherapy in an attempt to induce complete remission for stem cell collection and eventual autologous bone marrow transplantation. In September 2005, she completed four cyclophosphamide, adryamicin, vincristine and prednisone cycles plus a further four doses of rituximab, but bcl-2 bone marrow molecular positivity was induced to give two further doses of rituximab. In January 2006, molecular remission was obtained and high-dose cyclophosphamide plus growth factor were given, but the patient did not mobilize appreciable amounts of CD34 þ cells, so it was decided to continue with rituximab every 3 months. In January 2007, pancytopenia was observed with blast cells in peripheral blood. Bone marrow biopsy showed marked dysplastic changes, 20% CD34 þ blast cells and increased Factor VIII þ large elements. Cytologic examination showed 60% undifferentiated Sudan black negative blast cells. Cytogenetic analysis showed normal karyotype. She underwent induction chemotherapy without obtaining remission. Second-line chemotherapy induced response, and she underwent unrelated donor bone marrow transplantation but died of acute graft versus host disease in March 2007.
Comment
The reported incidence of secondary myeloid disorders following fludarabine-containing regimens, which has been reported to be 2.7%, 3 4% 4 and 7.3%, 5 in our series, approached 11%. A period of 44 and 33 months to tAML was comparable to previous observations. Although in patient 2, cyclophosphamide, adryamicin, vincristine and prednisone, and HDCTX may have contributed to AML, in patient 1 as few as four front-line FND-r were followed by leukemic evolution with the complex cytogenetic abnormalities commonly seen in tAML. 6 Base line normal hemogram and morphologic and karyotype analysis performed at the time of initial staging rule out a possible preexisting bone marrow disease.
In a large randomized comparative trial of fludarabine and novantrone versus cyclophosphamide, adryamicin, vincristine and prednisone with and without rituximab, fludarabine and novantrone arm showed higher rates of complete remission and no cases of secondary myelodysplastic syndromes/acute myeloid leukaemia. 7 However, this superiority did not translate into both progression-free survival and overall survival, and follow-up was too short (median 19 months, range 9-37) to detect eventual therapy-related myeloid disorders. Here we describe the complicated course of a 33-year-old African male with AIDS, with multiorgan failure due to multicentric Castleman's disease (MCD).
Multicentric Castleman's disease is a generalized lymphoproliferative disorder with poor prognosis. It is highly associated with HIV and human herpes virus-8 (HHV-8) infection. Overall mortality in HIV-positive patients is 70-85%, with a median survival of 8-14 months. A total of 15-20% develop intermediate-to high-grade non-Hodgkin lymphoma most commonly of the immunoblastic type.
1-3 MCD occurs
Letters to the Editor independently of high-activity antiretroviral therapy as well as CD4 þ cell count and viral load. Prognosis is poor, 2 especially when combined with further complications, and diagnosis is difficult, with histology showing plasmacellular infiltrates.
A variety of treatment approaches has been applied for MCD, including surgery (splenectomy), radiation, steroids, antiviral agents, interleukin-6 antibodies and single-agent or combined chemotherapy. However, since recommendations are based on case reports or small case series, there is no defined standard treatment for this rare and clinically heterogeneous disease. 3, 4 Recent reports suggest treatment of MCD with monoclonal anti-CD20 antibody rituximab due to detection of CD20 in mantlezone lymphoid cells from lymph nodes of HHV-8 related MCD. Especially, the combination of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) with rituximab showed remission with lower relapse rates compared with CHOP alone. 5 Furthermore antiviral HHV-8 treatment with ganciclovir appears to be efficient for HIV-positive patients. 6 We report on an HIV-positive African patient living in Germany since 1998. HIV infection was first diagnosed in 2001 after Salmonella sepsis, leading to acute renal failure, and was staged CDC C3 (4 CD4 þ T cells per microliter, 1.9 million copies HIV per ml). Since diagnosis of HIV, he had been hospitalized several times due to AIDS-defining diseases, including tuberculosis and HHV-8-positive Kaposi's sarcoma of both legs, treated effectively with radiation. HIV-specific therapy consisted of tenofovir, lamivudine and ritonavir.
On although inflammatory parameters were high with a 30-fold elevation of C-reactive protein (CRP), fibrinogen level of 545 mg dl À1 (reference 170-410 mg dl À1 ) and erythrocyte sedimentation rate of 99 mm h À1 . Probatory, calculated antibiotic therapy was started with ceftriaxone and levofloxacine.
Surgical lymph node excision and following evaluation through the Reference Center for Lymph Node Pathology, University of Wurzburg, finally led to diagnosis of an HHV-8-associated lymphoproliferative disease in terms of a plasmacellular MCD. Immunohistochemistry revealed strong positivity for HHV-8 (Figure 1) .
Additionally, he suffered from symmetric sensorimotoric neuropathy of the legs, hepatosplenomegaly and palmar as well as plantar hyperpigmentation. Immunoglobulin-G therapy was increased, using polyclonal agents, pointing at the POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes), which was shown to be associated with MCD. Flow chart. R, rituximab; CHP, cyclophosphamide adriamycin, prednisone; CT, detection of response to chemotherapy in CT; OP, splenectomy; lactate dehydrogenase limit o250 U l
À1
. CT, computed tomography.
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The patient's condition deteriorated rapidly, and shortly after admission he developed multiorgan failure, including cardiac and pulmonary insufficiency, acute renal failure and an acute abdomen under advancing hepatosplenomegaly, necessitating the transfer to the Medical Intensive Care Unit (MICU).
Creatinine maximum was 15.6 mg dl À1 and urea nitrogen maximum was 308 mg dl À1 (reference 0-1.2 and 12-46 mg dl À1 , respectively). Laboratory diagnostic workup furthermore revealed eightfold elevated lactate dehydrogenase (1979 U l À1 ) and nearly 100-fold elevated CRP serum levels (47.89 mg dl À1 ), respectively ( Figure 2) .
On admission to the MICU, APACHE II score was 26 and SAPS II score was 58. The patient was in need of vasopressors and was kept under artificial ventilation for 5 days. Continuous veno-venous hemodialysis was performed over 2 days, followed by intermittent hemodialysis for two additional weeks. Despite lack of pathogen detection, antibiotic treatment was conducted with meropeneme, vancomycin, linezolide and fluconazole. Furthermore, severe anemia was present (hemoglobin 5.7 g dl À1 ), with multiple anti-erythrocyte antibodies complicating transfusion.
Laboratory findings and clinical aggravation were interpreted as a possible transformation of MCD into a high-malignancy non-Hodgkin lymphoma. Due to the poor overall condition of the patient, a further diagnostic procedure was considered impossible. Despite the existing multiorgan failure, a combined chemotherapy (cyclophosphamide 750 mg m
À2
, day 1; adriamycin 50 mg m À2 , day 1 and prednisone 100 mg, days 1-5), including the monoclonal CD20 antibody rituximab (375 mg m À2 ), was initiated, immediately starting with two courses of rituximab. Due to pre-existing polyneuropathy, vincristine was omitted from the therapeutical strategy. Additionally, HHV-8 and associated Cytomegaloviral reactivation were treated with valganciclovir. The first course of rituximab was administered at the MICU. Again the patient was in need of catecholamines for 3 days as well as hemodialysis for 1 week; additionally oxygen was applied. After stabilization, a second course of rituximab was applied at our Department of Infectious Diseases. Subsequently rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) was administered three times in all (Figure 2) .
Under this treatment, clinical symptoms, lactate dehydrogenase and CRP improved significantly (Figure 2 ). CT scan showed distinct regression of peripheral lymphadenopathy as well as hepatosplenomegaly (Figure 2) .
One week after the third course of combined chemotherapy, temperature rose above 40 1C, again accompanied by rapid increase in CRP (Figure 2 ). Along with these symptoms, the patient suffered from severe abdominal pain. CT scan revealed confluent splenic abscesses with gastric fistulas. Therefore, splenectomy and gastric stitching were performed, revealing gastric perforation and abscess cavities in the spleen. Histological workup of the spleen through the Reference Center for Lymph Node Pathology revealed no more evidence of lymphoproliferative disease.
After rapid clinical recreation and improvement of laboratory values the patient was discharged, merely under HIV-specific therapy (ritonavir, emitricitabin, tenofovir, atazanavir). Treatment of HHV-8 reactivation was continued with valganciclovir. When the patient left the hospital, HIV-1 copies were 226 ml À1 of plasma, lactate dehydrogenase was normal and CRP was declining (Figure 2) . At the last follow-up 20 months after diagnosis of MCD, the patient presented in good general condition with normal laboratory reports, no further complications and no evidence of MCD relapse. Medication consisted solely of antiretroviral drugs. Since no relapse was seen up to now under the mentioned combined immunotherapy of merely three courses of R-CHP, the original suspicion of transformation in a high-grade non-Hodgkin lymphoma appears to be false.
Here we present the complicated case of an HIV-positive patient with pre-existing AIDS-defining diseases suffering from HHV-8 associated MCD. We successfully treated this patient with two courses of rituximab followed by three courses of R-CHP, valganciclovir and final splenectomy despite presentation in multiorgan failure. Twenty months after diagnosis of MCD, the patient presented in excellent health condition with normal laboratory reports and no evidence of relapse.
In summary, treatment of this HIV-positive MCD patient with multiorgan failure with rituximab, prednisolone, doxorubicin, cyclophosphamide and valganciclovir, followed by splenectomy, was effective. Therefore, we encourage physicians to administer combined immunotherapy to patients with MCD despite limited general condition. 
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